

The VIVA HEALTH Medical Preferred Drug program has been developed to encourage the use of Preferred Drugs. For all drugs (Preferred and Non-Preferred), the member is required to meet the respective standard Utilization Review Medical Policy criteria. This program also directs the patient to try a Preferred Product(s) prior to the approval of a Non-Preferred Product(s).

DRUG CLASS	PREFERRED PRODUCT(S)	NON-PREFERRED PRODUCT(S)
Adrenocorticotrophic Hormone	H.P. Acthar	N/A
AHP	Givlaari	N/A
Bevacizumab	Mvasi, Zirabev, Alymsys	Avastin, Vegzelma
Botulinum Toxins	Botox, Xeomin, Dysport, Daxxify	Myobloc
Enzyme Replacement Therapy	Cerezyme	Elelyso, Vpriv
Erythropoiesis Stimulating Agents	Retacrit, Procrit, Aranesp	Epogen
Fabry Disease	Elfabrio	Fabrazyme
Gene Therapy (Miscellaneous)	Zolgensma, Vyjuvek, Lenmeldy	N/A
Gene Therapy (Beta Thalassemia)	Zyntelgo, Casgevy	N/A
Gene Therapy (Hemophilia)	Hemigenix, Roctavian, Beqvez	N/A
Gene Therapy (Sickle Cell Disease)	Lyfgenia, Casgevy	N/A
GnRH (Central Precocious Puberty)	Triptodur, Supprelin LA, Lupron Depot-Ped	Fensolvi
GnRH (Gynecological)	Lupron Depot	N/A
GnRH (Prostate Cancer)	Camcevi, Firmagon, Eligard	Trelstar, Lupron
hATTR	Onpattro, Amvuttra	N/A
Hemophilia A	Kogenate, Kovaltry, Jivi, Altuviiiio	N/A
Hyaluronic Acid Derivatives	Monovisc, Orthovisc, Synvisc, Synvisc-One	Durolane, Gelsyn 3, Supartz FX, Euflexxa, Hyalgan, Hymovis, Triluron, Trivisc, Gel-One, Visco-3, GenVisc 850, Synjoynt/sodium hyaluronate injection
Inflammatory Conditions	Entyvio IV, Simponi Aria, Stelara, Cimzia, Ilumya, Skyrizi, Omvoh, Cosentyx IV, Tremfya	Orencia
Inflammatory Conditions (Tocilizumab Products)	Tyenne	Actemra, Tofidence
Infliximab	Avsola, Inflectra	Remicade/infliximab, Renflexis
Infliximab SQ*	Zymfentra	
IUD	Kyleena, Mirena, Skyla, Liletta	N/A
IVIG	Asceniv, Bivigam, Alyglo	N/A

*Refer to the pharmacy benefit for a subcutaneous Calcitonin Gene-Related Peptide Inhibitor and PCSK9.

DRUG CLASS	PREFERRED PRODUCT(S)	NON-PREFERRED PRODUCT(S)
IV Iron	Ferrlecit, INFeD, Venofer	Feraheme, Injectafer, Monoferric
Keratolytic	Ycanth	N/A
LA- GCSF (pegfilgrastim)	Neulasta, Udenyca, Stimufend	Ziextenzo, Fylnetra, Fulphila, Nyvepria
LA- GCSF (eflapegrastim)	Rolvedon	N/A
Long Acting Injectables	Rykindo	N/A
Migraine*	Ajovy, Aimovig, Emgality	Vyepti
MS	Ocrevus, Tysabri, Briumvi, Ocrevus Zunovo	N/A
Neurology	Soliris, Ultomiris, Vyvgart, Vyvgart Hytrulo, Rystiggo	N/A
Oncology- Monoclonal Antibody Combination Products	Phesgo	N/A
Paroxysmal Nocturnal Hemoglobinuria	Soliris, Ultomiris	PiaSky
PCSK9*	Praluent, Repatha	Leqvio
PH1	Oxlumo	N/A
Pulmonary Arterial Hypertension	Treprostinil	Remodulin
Rituximab	Ruxience, Truxima, Riabni	Rituxan, Rituxan Hycela
SA- GCSF	Zarxio, Nivestym	Neupogen, Granix, Releuko
SCIG	Cutaquig, Hizentra, Xembify, Cuvitru	
SLE	Benlysta	Saphnelo
Specialty Asthma – IL-5's	Fasenra, Nucala	Cinqair
Specialty Asthma – Other	Xolair, Tezspire	N/A
Trastuzumab	Kanjinti, Trazimera, Ogivri	Herceptin, Herceptin Hylecta, Ontruzant, Herzuma, Hercessi

*Refer to the pharmacy benefit for a subcutaneous Calcitonin Gene-Related Peptide Inhibitor and PCSK9.